These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 11590520

  • 1. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.
    Jensen-Fangel S, Kirk O, Blaxhult A, Gerstoft J, Pedersen C, Black FT, Lundgren JD, Obel N.
    HIV Clin Trials; 2001; 2(2):122-7. PubMed ID: 11590520
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA, Borleffs JC.
    AIDS; 1999 May 07; 13(7):F53-8. PubMed ID: 10357371
    [Abstract] [Full Text] [Related]

  • 3. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 4. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.
    Jensen-Fangel S, Kirk O, Larsen L, Blaxhult A, Gerstoft J, Pedersen C, Black FT, Lundgren JD, Obel N.
    Scand J Infect Dis; 1999 Dec 10; 31(5):489-93. PubMed ID: 10576129
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: does it affect long-term treatment outcome?
    Jensen-Fangel S, Pedersen C, Nielsen H, Tauris P, Møller A, Sørensen HT, Obel N.
    Scand J Infect Dis; 2003 Dec 10; 35(10):743-9. PubMed ID: 14606614
    [Abstract] [Full Text] [Related]

  • 8. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 10; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
    Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, Miller V, Viard JP, Phillips AN, Lundgren JD, EuroSIDA Study Group.
    AIDS; 2001 May 25; 15(8):999-1008. PubMed ID: 11399982
    [Abstract] [Full Text] [Related]

  • 10. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM, Winters MA, Lawrence J, Merigan TC.
    AIDS; 1999 Feb 25; 13(3):359-65. PubMed ID: 10199226
    [Abstract] [Full Text] [Related]

  • 11. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
    Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D.
    AIDS; 2000 Jan 28; 14(2):141-9. PubMed ID: 10708284
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.
    AIDS; 1999 Jul 30; 13(11):F71-7. PubMed ID: 10449277
    [Abstract] [Full Text] [Related]

  • 13. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP, Plosker GL.
    Drugs; 2000 Aug 30; 60(2):481-516. PubMed ID: 10983742
    [Abstract] [Full Text] [Related]

  • 14. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P.
    Antivir Ther; 2004 Apr 30; 9(2):247-56. PubMed ID: 15134187
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
    Hellinger JA, Cohen CJ, Stein AJ, Gallant JE, Gathe J, Keiser P.
    HIV Clin Trials; 2000 Apr 30; 1(2):25-8. PubMed ID: 11590495
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study.
    Sension MG, Farthing C, Shaffer AG, Graham E, Siemon-Hryczyk P, Pilson RS.
    AIDS Patient Care STDS; 2001 Mar 30; 15(3):129-36. PubMed ID: 11313025
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, Moreno S, NELSANE Study.
    AIDS Res Hum Retroviruses; 2001 Jan 20; 17(2):93-8. PubMed ID: 11177388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.